and evaluated – Alimta and Bevacizumab
(given through an infusion in the vein) and Tarceva (given in pill form).
Dr. Melvyn Tockman, member of the Thoracic Oncology Program, can comment on lung cancer prevention for people with increased risk. Beginning in October, Tockman and his team are recruiting participants for a lung cancer prevention study. Eligible participants must be between45 – 79 years of age, current smokers or have stopped within the past year. Participants must be free of lung cancer. The purpose of this study is to find out what effects sulindac has on the risk of developing lung cancer. Sulindac is a drug typically used for arthritis It is expected that each participant will be enrolled in the trial for about six months, and may be contacted by telephone after this treatment period to check on overall health status.
Dr. Gerold Bepler, Leader, Thoracic Oncology Program, can comment on lung cancer prevention for former smokers. In October, Bepler and his team will be recruiting for a new trial for former smokers. Eligible participants must be 45 years of age or older and be former smokers who have stopped smoking for more than a year. The purpose of this trial is to develop a treatment that prevents the development of lung cancer and to identify changes in airway cells that may lead to lung cancer. The trial uses an investigational drug, Enzastaurin, and it is expected that each participant will be enrolled in the trial for approximately six months, but may be contacted by telephone up to one to two years after completion of treatment to check on overall health status.
Great American Smokeout (Nov. 16)
Thomas Brandon, Ph.D., Director of the Tobacco Research & Intervention Program, says it is well know that certain cues or triggers can cause cravings among smoking addicts. For a smoker who is ready to quit, just seeing a cigarette smoldering in an ashtray can be a powerful source of temptation. Brandon and his team of researchers are recruiting about 150 smokers for a study to develop and test new forms of “cue exposure therapy” to help smokers avoid the urges associated with these triggers. In addition to nicotine patchesand counseling sessions, participants will receive training to resist the sight of common smoking triggers presented on a video monitor, including personal triggers that they photographed with a digital camera. The study is funded by the American Cancer Society.
David Drobes, Ph.D. – Associate Director of Tobacco Research and Intervention Program, and his team are recruiting cigarette smokers for several short-term studies to examine their reactions to words and pictures. Eligible participants are not trying to quit smoking, have no major health problems, and are not taking medications. Participants
will have physiological measures taken while looking at pictures on a computer screen, or they will be asked to press a button when certain pictures or words appear. Each study lasts from one to three hours, and compensation is provided
In 2001, H. Lee Moffitt Cancer Center & Research Institute earned NCI Comprehensive Cancer Center status in recognition of its excellence in research and contributions to
clinical trials, prevention and cancer control. Additionally, Moffitt is a member of the
National Comprehensive Cancer Network, a prestigious alliance of the country's leading cancer centers, and is listed in the U.S. News & World Report as one of the top cancer hospitals in America. Moffitt’s sole mission is to contribute to the prevention and cure of cancer.